Stem Cell Transplantation for Myelofibrosis — CPB 0838 | AETNA Coverage Update

Aetna modified CPB 0838 governing stem cell transplantation for myelofibrosis, effective December 10, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated this coverage policy to clarify both covered and non-covered indications for hematopoietic cell transplantation (HCT) in myelofibrosis patients. The policy covers CPT codes 38204 through 38215, 38230, 38240, and 38242 for allogeneic transplant services—when specific medical necessity criteria are met. Two codes, 38232 and 38241, are explicitly excluded under this policy. If your team bills HCT for myelofibrosis under ICD-10 D75.81, this update directly affects your prior authorization strategy and claim denial risk.

---

Field	Detail
Payer	Aetna
Policy	Stem Cell Transplantation for Myelofibrosis
Policy Code	CPB 0838 Aetna
Change Type	Modified
Effective Date	December 10, 2025
Impact Level	High
Specialties Affected	Hematology, Oncology, Bone Marrow Transplant Programs, Hospital Revenue Cycle
Key Action	Audit all pending and upcoming HCT prior authorization requests against the five medical necessity criteria before submitting claims under D75.81

---

Aetna Stem Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The core of this Aetna myelofibrosis coverage policy comes down to five criteria. Meet any one of them and allogeneic HCT—both ablative and non-myeloablative—qualifies as medically necessary.

Here are the five criteria, exactly as the policy states:

That fifth criterion is the broadest and the most commonly applicable. Risk stratification tools like DIPSS or IPSS-Plus classify most transplant-eligible MF patients as intermediate-2 or high risk. If your clinical team is using those tools and documenting risk category, you have a clear path to medical necessity. Make sure that documentation makes it into your prior authorization package.

Repeat allogeneic HCT also qualifies as medically necessary under this policy. The criteria are narrower: the patient must have primary graft failure or documented relapse. This matters for billing teams managing multi-episode cases. Document graft failure or relapse explicitly in your auth request—don't assume the payer will infer it from clinical notes.

Aetna doesn't publish its prior authorization requirements directly in CPB 0838, but HCT is universally subject to prior auth under commercial plans. Treat every case as requiring prior authorization unless your contract explicitly states otherwise. Missing this step is the fastest path to a claim denial on a six-figure case.

Reimbursement for these procedures is substantial. A myelofibrosis HCT episode—covering donor search, harvest, processing, and transplant—can represent hundreds of thousands of dollars in charges. Getting the medical necessity documentation right before the effective date of your claim is not optional.

---

Aetna Myelofibrosis HCT Exclusions and Non-Covered Indications

This is where CPB 0838 gets specific in ways that will directly affect your claim denial rate. Aetna lists seven interventions as experimental, investigational, or unproven for myelofibrosis. None of these will get paid.

Autologous HCT is not covered. CPT codes 38232 (bone marrow harvesting, autologous) and 38241 (hematopoietic progenitor cell, autologous transplantation) are explicitly excluded. This is a hard line. Autologous transplant for myelofibrosis has no evidence base strong enough for Aetna to cover it, and this policy makes that explicit.

Pre-HCT ruxolitinib is not covered as a transplant-preparatory intervention. Ruxolitinib (Jakafi) is commonly used to manage MF symptoms, and some centers use it as a bridge to transplant. Aetna's position is that using it specifically as pre-HCT conditioning is still experimental. If your oncology team administers ruxolitinib before conditioning, document it as disease management—not as transplant preparation—or you risk a coverage denial on the drug component.

Splenic irradiation before HCT is not covered. This appears twice in the policy, once as a general statement and once specifically tied to pre-conditioning. Both are excluded. If your center uses splenic irradiation as a standard pre-transplant protocol, flag those cases before billing.

Mutational profiling for post-HCT prognosis is not covered. Using genetic biomarkers to assess outcomes after transplant falls into the experimental category. This is clinically relevant as genomic testing becomes more common in hematology. The cost of these panels can be significant—don't bill them as part of the HCT episode expecting coverage.

AI-based risk stratification is not covered. Aetna explicitly calls out machine learning and deep learning models used for MF risk stratification. If your institution uses AI tools for this purpose, those charges won't be reimbursable under this policy.

Mesenchymal stem cell infusions combined with allogeneic transplant are not covered. Allogeneic HCT combined with transfusion of mesenchymal stem cells for MF treatment is experimental. Keep this combination off your billing for Aetna patients.

---

Coverage Indications at a Glance

---

Aetna Myelofibrosis HCT Billing Guidelines and Action Items 2025

The effective date for this modified policy is December 10, 2025. If you have cases in the pipeline now, act before that date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Stem Cell Transplantation for Myelofibrosis Under CPB 0838

Covered CPT Codes (When Selection Criteria Are Met)

These codes cover allogeneic bone marrow and stem cell services. Coverage applies when at least one of the five medical necessity criteria is documented and prior authorization is obtained.

Not Covered / Experimental Codes

These codes are excluded for myelofibrosis under CPB 0838. Autologous HCT is considered experimental for this diagnosis.

Code	Type	Description	Reason Copy
38232	CPT	Bone marrow harvesting for transplantation; autologous	Autologous HCT for myelofibrosis is experimental/investigational
38241	CPT	Hematopoietic progenitor cell (HPC); autologous transplantation	Autologous HCT for myelofibrosis is experimental/investigational

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
D75.81	Myelofibrosis

---